WEgovy Real World Assessment of Weight Loss in Korea

NCT07280221 · Enrolling by invitation

Last updated 2026-05-28

This study is testing how well a weight-loss medication works in adults with obesity in real-world settings in Korea.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 500 people Planned (estimated).

Who can join Ages 19+ · all sexes

Timeline Started 2025-11 · est. completion 2027-10

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT07280221 ↗

Description as written by the study sponsor.

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Treatments tested

Semaglutide Drug

Semaglutide injection will be self-administered once weekly subcutaneously.

Main thing measured	Percentage change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07280221 ↗